Further pilot clinical study showed that although blood occludin significantly elevated in AIS compared with pseudo-stroke patients, blood occludin alone is not sufficient enough for HT prediction (AUC 0.73–0.77) (Li et al., 2020). This evidence concerns the gene OCLN and androgen insensitivity syndrome.